Keyphrases
Immune Response
100%
COVID-19
100%
COVID-19 Booster Vaccination
100%
Third Dose
100%
Omicron Infection
100%
Healthcare Workers
66%
Second Dose
66%
T Cell Activation
50%
Neutralizing Antibodies
50%
T Cells
33%
Antibody Titer
33%
Mononuclear Cells
33%
IgG Antibody
33%
Ratio of Means
33%
BNT162b2 Vaccine
33%
Israel
16%
Vaccination
16%
Quantitative PCR
16%
Tertiary Care Hospital
16%
Two-dose
16%
Linear Mixed Model
16%
IgG Levels
16%
Response Dynamics
16%
Antibody Dynamics
16%
Humoral Response
16%
Susceptibility to Infection
16%
Pfizer
16%
Geometric Mean Titer
16%
BNT162b2
16%
Longitudinal Cohort Study
16%
SARS-CoV-2 Variants
16%
Booster Dose
16%
Variants of Concern
16%
Delta Variant of Concern
16%
Omicron Variant
16%
Antibody Kinetics
16%
IgG Avidity
16%
Peak Ratio
16%
Prospective Longitudinal Cohort
16%
SARS-CoV-2 Omicron
16%
BioNTech
16%
Microneutralization
16%
Antibody Waning
16%
High Efficiency
16%
Immunology and Microbiology
COVID-19
100%
Omicron Coronavirus Variant
100%
Immune Response
100%
Vaccination Policy
100%
Vaccine Efficacy
50%
T Cell
40%
Neutralizing Antibody
30%
Severe Acute Respiratory Syndrome Coronavirus 2
20%
Neutralization
20%
Dynamics
20%
Cell Activity
20%
Mononuclear Cell
20%
Immunoglobulin G Antibody
20%
Antibody Titer
20%
T Cell Activation
10%
Humoral Immunity
10%
Titer
10%
Reverse Transcription Polymerase Chain Reaction
10%
Booster Dose
10%
Wild Type
10%
Medicine and Dentistry
Infection
100%
Immune Response
100%
COVID-19
100%
Omicron Coronavirus Variant
100%
T Cell
40%
Health Care
40%
Neutralizing Antibody
30%
Mononuclear Cell
20%
Neutralization
20%
Immunoglobulin G Antibody
20%
Cell Activity
20%
Severe Acute Respiratory Syndrome Coronavirus 2
20%
Cohort Analysis
10%
Reverse Transcription Polymerase Chain Reaction
10%
Mixed Model
10%
T Cell Activation
10%
Booster Dose
10%
Humoral Immunity
10%
Biochemistry, Genetics and Molecular Biology
Immune Response
100%
T Cell
100%
Titer
60%
Neutralizing Antibody
60%
Avidity
40%
Dynamics
40%
Cell Activity
40%
SARS Coronavirus
40%
Wild Type
20%
Cohort Study
20%
Reverse Transcription Polymerase Chain Reaction
20%
Cell Activation
20%
Humoral Immunity
20%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Vaccination Policy
100%
Neutralizing Antibody
50%
SARS Coronavirus
33%
Immunoglobulin G Antibody
33%
Cohort Study
16%
Mixed Model
16%
Delta Variant
16%
RNA Directed DNA Polymerase
16%